* If you want to update the article please login/register
Chiauranib in particular demonstrated high selectivity in the kinase inhibition profile with little activity on off-target non-receptor kinases, proteins, GPCR, and ion channels, indicating a higher drug safety profile in terms of clinical relevance. This trial is a material balance review of [14C]Chiauranib's infected with small cell lung cancer, with the intention of learning more about the drug's absorption, metabolism, and excretion in the human body, as well as monitoring the patients' health after therapy.
Source link: https://clinicaltrials.gov/ct2/show/NCT05371899
This is an open-label research to determine the PK and excretion of a single oral dose of [14C]-rodatristat ethyl. Following completion of the eligibility requirements, approximately 6 healthy male subjects will join the clinical unit, and the following morning, a single oral suspension of rodatristat ethyl 600 mg containing a mixture of [12C]-rodacristat ethyl and [14C]-rodatristat ethyl 600 mg containing a mixture of [12C]-rodacristat ethyl and [14C]-rodatristat ethyl and [12C]-roda ethyl and [12C]-ethyl ethyl and [12C]-roda microcuryl ethyl and [14C]-roda[14C]-rodayl and [14C]-roda microcuryl and [14C]-rodacristat ethyl and [14C]-rodadatristat ethyl and [14C]- Following dosing, serial whole blood and plasma PK tests, urine and feces samples will be collected until discharge. Subjects will remain in the clinic until at least Day 7. Subjects will be discharged if complete recovery of the administered radioactive dose is u22600%; on two days in which a fecal sample is obtained, the total daily average recovery of the radioactive dose is u226461 percent. If not, patients will remain in the clinic until these requirements are followed, but not longer than 15 days.
Source link: https://clinicaltrials.gov/ct2/show/NCT05006118
Cancer is a disease in which cells in a specific area of the body grow and reproduce uncontrollably, resulting in a tumour formation. Breast, lung, prostate, and bowel cancer are among the four most common forms of cancer in the United Kingdom. The test medicine is marked as 'Radiolabelled', which allows us to track where the test medicine is located in the body. Volunteers will be given a single dose of 2 non-radiolabelled oral tablets in the fasted state followed by an intravenous injection of radiolabelled test medicine 1 hour 15 mins minutes later. Volunteers will be discharged on Day 8, but individuals will be required to stay at the medical unit until Day 10 if the mass balance conditions are not met by Day 8. Volunteers will receive a follow-up phone call between Day 15 and Day 19.
Source link: https://clinicaltrials.gov/ct2/show/NCT05419401
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions